M. Barone

Characterization of two novel cell lines, DERL-2 (CD56+/CD3+/TCRγδ+) and DERL-7 (CD56+/CD3−/TCRγδ−), derived from a single patient with CD56+ non-Hodgkin's lymphoma

P. Boccuni, F. Salvatore, M. Intrieri, 2001, Leukemia.

KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life: a retrospective survey in 123 patients

F. Ferrara, A. Sica, F. Pane, 2020, Annals of Hematology.